Tiger Buford – retained recruiter dissecting orthopedics 
The ONLY orthopedic-related company to pursue the public markets since Monogram (2023) and Treace (2021) is HingeHealth – https://www.hingehealth.com/
On March 10, 2025, Hinge Health’s S-1 filing went live, signaling its intent to pursue an IPO under the ticker symbol $HNGE. Hinge Health specializes in digital health solutions for musculoskeletal (MSK) conditions, offering virtual physical therapy, wearable sensors, and personalized treatment plans—technologies that align with orthopedic care by addressing joint and muscle issues non-surgically. While not a traditional orthopedic implant manufacturer, its focus on MSK health positions it within the broader orthopedic medical device ecosystem.
Reported Sales (Revenue)
2023 Revenue: $292 million
2024 Revenue: $390 million
Read the S-1 Filing
Hinge Health Files Registration Statement for Proposed Initial Public Offering (press release)
SAN FRANCISCO – March 10, 2025 – Hinge Health announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Hinge Health intends to list its Class A common stock on the New York Stock Exchange under the ticker symbol “HNGE.”
Morgan Stanley, Barclays and BofA Securities are acting as lead book-running managers for the proposed offering. Evercore ISI, RBC Capital Markets, Truist Securities, Stifel, William Blair, Piper Sandler, Canaccord Genuity, KeyBanc Capital Markets, Needham & Company, Raymond James, and KKR Capital Markets LLC are also acting as book-running managers.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or email: prospectus@morganstanley.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email: barclaysprospectus@broadridge.com, or by telephone: (888) 603-5847; or BofA Securities, Inc., NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, by email: dg.prospectus_requests@bofa.com, or by telephone: (800) 294-1322.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Hinge Health
Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for its clients. The company has designed its platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation—and the platform can help to ease members’ pain, improve their function, and reduce their need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere. The company is headquartered in San Francisco, California.
Media Contact: media@hingehealth.com
Investor Relations Contact: ir@hingehealth.com